Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

The Greater Middle East is home to a rich genetic diversity that remains largely untapped in genomic research. This Perspective explores its potential for rare disease research, obstacles limiting ...

Inc. (NASDAQ:OM), a medical technology company focused on innovating dialysis treatment, has resolved all concerns raised in a Warning Letter from the U.S. Food and Drug Administration (FDA) dating ...

We are pleased to achieve this important milestone and remain vigilant as we work to continuously improve everything we do on behalf of the patients and providers we serve.” About Outset Medical, Inc.

Outset Medical (OM) announced it has been notified by the FDA that all issues cited in a warning letter the company received in July of 2023 ...

Outset Medical (OM) said that all of the issues cited in a warning letter from the FDA in July 2023 have been addressed. Read more here.

The case against the former nurse has been extremely complex from the outset - not least because ... Instead, prosecutors had to draw on technical medical evidence - along with statistical data ...

SAN JOSE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and ...

Outset Medical also borrowed $100 million as an initial term loan from Perceptive Credit Holdings IV, LP, which, along with cash reserves, was used to repay existing debts.